Status:
UNKNOWN
Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Brief Summary
This is a real world study to evaluate the efficacy and safety of tyrosine kinase inhibitors after T-DM1 progression.
Detailed Description
HER2-positive breast cancers account for 15%-20% of all breast cancers. The development of HER2 targeted therapies have greatly improved the survival of HER2-positive breast cancer patients. Trastuzum...
Eligibility Criteria
Inclusion
- Female and 18-70 years old
- Metastatic or locally recurrent HER2-positive breast cancer
- Patients received TKIs-based therapy after T-DM1 failure in treatment for metastasis
- Complete and accurate medical data
Exclusion
- \- Incomplete medical data
Key Trial Info
Start Date :
August 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05231863
Start Date
August 1 2019
End Date
December 1 2022
Last Update
February 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China